V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Altimmune Executive Compensation (FY25)

ALT · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Vipin Garg
Latest say-on-pay support
=
April 16, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Altimmune

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): April 16, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Altimmune brief$1,500Get the executive brief
Velarion Member, one year
264 figures on this page: 254 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.

More on Altimmune

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Vipin Garg: $6,090,462 → $8,026,590 (31.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Altimmune's chief executive and what were they paid?
Vipin Garg, Chief Executive Officer, received $8,026,590 in total compensation for fiscal 2025. Garg's total moved 31.8% higher from the $6,090,462 reported for fiscal 2024.
What was Altimmune's say-on-pay result?
The say-on-pay proposal drew 76.8% support at the meeting held April 16, 2026 for fiscal 2025.
Which companies are in Altimmune's peer group?
The disclosed peer group names 89bio, Inc., Akero Therapeutics, Inc., Amylyx Pharmaceuticals, Inc., Anavex Life Sciences Corp. and Arbutus Biopharma Corporation, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vipin Garg
Chief Executive Officer
◇—◇◇◇—◇◇
M. Scott Harris
Chief Medical Officer
◇—◇◇◇—◇◇
M. Scot Roberts
Chief Scientific Officer
◇—◇◇◇—◇◇
Richard Eisenstadt
Chief Financial Officer
◇———◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vipin Garg
Chief Executive Officer
◇—◇◇◇—◇◇
Raymond Jordt
Chief Business Officer
◇—◇◇◇—◇◇
M. Scott Harris
Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vipin Garg
Chief Executive Officer
◇—◇◇◇—◇◇
M. Scott Harris
former Chief Medical Officer
◇—◇◇◇—◇◇
M. Scot Roberts
Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vipin Garg
Chief Executive Officer
◇◇◇◇◇—◇◇
M. Scott Harris
former Chief Medical Officer
Departed during or after this year
◇◇◇◇◇—◇◇
Christophe Arbet-Engels
Chief Medical Officer
◇◇◇◇◇—◇◇
M. Scot Roberts
Chief Scientific Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christophe Arbet-EngelsRSU——————◇
Christophe Arbet-EngelsOption——————◇
Dr. SohnOPTION◇——◇—◇◇
DursoOPTION◇——◇—◇◇
DursoRSU◇——◇——◇
M. Scot RobertsOPTION◇——◇—◇◇
M. Scot RobertsRSU◇——◇——◇
M. Scott HarrisRSU◇——◇——◇
M. Scott HarrisOPTION◇——◇—◇◇
Vipin GargRSU◇——◇——◇
Vipin GargOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
M. Scott HarrisRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/25/2034
Option◇—◇1/27/2035
RSU◇◇——
Option◇—◇2/2/2032
Option◇—◇1/30/2033
M. Scot RobertsRSU◇◇——
Option◇—◇1/30/2033
Option◇—◇1/27/2035
RSU◇◇——
Option◇—◇2/2/2032
RSU◇◇——
RSU◇◇——
Option◇—◇1/25/2034
Vipin GargRSU◇◇——
RSU◇◇——
Option◇—◇2/2/2032
RSU◇◇——
RSU◇◇——
Option◇—◇1/30/2033
Option◇—◇1/25/2034
Option◇—◇1/27/2035
Christophe Arbet-EngelsOption◇—◇10/1/2035
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Christophe Arbet-Engels
Chief Medical Officer · Employment agreement · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
M. Scot Roberts
Chief Scientific Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jerome Durso
Board chair
◇◇◇———◇
Catherine Sohn, Pharm D
◇—◇———◇
Philip L. Hodges
◇—◇———◇
Wayne Pisano
◇—◇———◇
Mitchel Sayare, Ph.D
◇—◇———◇
John M. Gill
◇—◇———◇
Klaus O. Schafer, M.D., MPH
◇—◇———◇
Diane K. Jorkasky, M.D
◇—◇———◇
Teri Lawver
◇—◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 89bio, Inc. ETNB
  • Akero Therapeutics, Inc. AKRO
  • Amylyx Pharmaceuticals, Inc. AMLX
  • Anavex Life Sciences Corp. AVXL
  • Arbutus Biopharma Corporation ABUS
  • Arcturus Therapeutics Holdings Inc. ARCT
  • Astria Therapeutics, Inc. ATXS
  • Atea Pharmaceuticals, Inc. AVIR
  • aTyr Pharma, Inc. ATYR
  • Gossamer Bio, Inc. GOSS
  • Inhibrx Biosciences, Inc. INBX
  • MBX Biosciences, Inc. MBX
  • Rezolute, Inc. RZLT
  • Savara Inc. SVRA
  • Solid Biosciences Inc. SLDB
  • Terns Pharmaceuticals, Inc. TERN
  • Tyra Biosciences, Inc. TYRA

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 16, 2026=◇◇◇
2024September 25, 2025=◇◇◇
2023September 26, 2024=◇◇◇
2022September 28, 2023=◇◇◇
2021September 29, 2022=◇◇◇
2020September 23, 2021=◇◇◇
2019September 24, 2020=◇◇◇
2018September 26, 2019=◇◇◇
2017August 30, 2018=◇◇◇
2016October 13, 2017=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Vipin Garg (Chief Executive Officer), FY2025 total compensation $8,026,590 (base salary $658,694) [exec_comp, SEC accession 0001104659-26-028953, filed 2026-03-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Altimmune files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Altimmune disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Altimmune sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Altimmune's disclosed peer group is defensible, who names Altimmune back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
264 figures on this page: 254 cited to the filing that reported them, 10 calculated from figures it prints.
254 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001326190-26-000027
    Proposal No. 3 : Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal).
  2. 0001104659-26-028953
    ELECTION OF DIRECTORS · EXECUTIVE COMPENSATION · Summary Compensation Table
  3. 0001326190-25-000050
    Proposal No. 3 : Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal).
  4. 0001326190-24-000042
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001326190-24-000038
  6. 0001326190-23-000040
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001558370-23-015034
  8. 0001326190-22-000007
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001104659-21-119390
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-20-254566
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-19-259847
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-18-265020
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-17-312751
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-17-256136
    Exhibit
  15. 0001326190-26-000018
    Exhibit
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Altimmune executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ALT (accessed 2026).
Short form: data: Velarion

The paid brief for Altimmune

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Altimmune and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Altimmune discloses

The companies named in ALT's own disclosed peer group.

89bio, Inc.Akero Therapeutics, Inc.Amylyx Pharmaceuticals, Inc.Anavex Life Sciences Corp.Arbutus Biopharma CorporationArcturus Therapeutics Holdings Inc.Astria Therapeutics, Inc.Atea Pharmaceuticals, Inc.aTyr Pharma, Inc.Gossamer Bio, Inc.Inhibrx Biosciences, Inc.MBX Biosciences, Inc.Rezolute, Inc.Savara Inc.Solid Biosciences Inc.Terns Pharmaceuticals, Inc.Tyra Biosciences, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy